Published in N Engl J Med on May 27, 2004
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst (2006) 6.02
Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila) (2008) 2.43
Cancer diagnosis in primary care. Br J Gen Pract (2010) 2.24
Distribution of PSA velocity by total PSA levels: data from the Baltimore Longitudinal Study of Aging. Urology (2011) 1.51
Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene. Br J Cancer (2005) 1.31
A Review on the Clinical Utility of PSA in Cancer Prostate. Indian J Surg Oncol (2012) 0.80
Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA) screening. BMC Cancer (2011) 0.79
Accuracy of a high prostate-specific antigen level for prostate cancer diagnosis upon initial biopsy in Korean men. Yonsei Med J (2007) 0.78
Detecting Prostate Cancer with Molecular Markers: uPM3. Rev Urol (2005) 0.77
Translation research in prostate cancer. Rev Urol (2006) 0.75
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA (1994) 9.15
A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA (1995) 8.60
Enthusiasm for cancer screening in the United States. JAMA (2004) 8.22
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA (1992) 6.40
Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med (1996) 5.68
Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst (1999) 2.48
Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology (2000) 2.10
Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA (1996) 1.97
Trends in prostate cancer mortality among black men and white men in the United States. Cancer (2003) 1.82
Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA (1997) 1.80
Patterns of progression in prostate cancer. Lancet (1986) 1.78
Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology (2003) 1.62
Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol (1990) 1.49
Clinical evidence for and implications of the multistep development of prostate cancer. J Urol (1990) 1.32
Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology (1999) 1.11
Serendipity in detecting disease in low prostate-specific antigen ranges. BJU Int (2002) 0.96
Prostate-specific antigen levels from completely sectioned, clinically benign, whole prostates. Cancer (1991) 0.92
Complications after prostate biopsy: data from SEER-Medicare. J Urol (2011) 5.40
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol (2013) 4.20
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17
Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare. J Urol (2012) 4.11
Prostate specific antigen best practice statement: 2009 update. J Urol (2009) 3.95
Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst (2006) 2.96
Baseline prostate-specific antigen testing at a young age. Eur Urol (2011) 2.95
Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol (2013) 2.66
What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol (2010) 2.49
Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med (2008) 2.33
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab (2006) 2.17
Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol (2009) 2.17
Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. J Urol (2009) 2.09
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol (2007) 2.02
Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol (2004) 1.85
Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol (2012) 1.80
PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol (2008) 1.78
ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. Urology (2011) 1.71
Prostate specific antigen testing among the elderly--when to stop? J Urol (2009) 1.62
Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int (2009) 1.59
Geometric evaluation of systematic transrectal ultrasound guided prostate biopsy. J Urol (2012) 1.59
Disparities in treatment and outcome for renal cell cancer among older black and white patients. J Clin Oncol (2007) 1.56
Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev (2005) 1.55
Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance. BJU Int (2013) 1.55
Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy. Urology (2012) 1.54
Active surveillance versus surgery for low risk prostate cancer: a clinical decision analysis. J Urol (2012) 1.54
Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol (2013) 1.53
Distribution of PSA velocity by total PSA levels: data from the Baltimore Longitudinal Study of Aging. Urology (2011) 1.51
Risk stratification of men choosing surveillance for low risk prostate cancer. J Urol (2010) 1.47
Anatomic extent of pelvic lymph node dissection: impact on long-term cancer-specific outcomes in men with positive lymph nodes at time of radical prostatectomy. Urology (2013) 1.47
Calcium intake and prostate cancer risk in a long-term aging study: the Baltimore Longitudinal Study of Aging. Urology (2002) 1.46
Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology (2005) 1.46
Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer. BJU Int (2012) 1.44
Efficacy of periprostatic local anesthetic for prostate biopsy analgesia: a meta-analysis. Urology (2006) 1.40
Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. J Urol (2008) 1.30
Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis. J Urol (2013) 1.30
Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res (2009) 1.26
Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res (2012) 1.25
Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev (2005) 1.13
Primary care providers' response to the US Preventive Services Task Force draft recommendations on screening for prostate cancer. Arch Intern Med (2012) 1.08
Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level. J Urol (2009) 1.08
Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol (2003) 1.03
Prostate specific antigen best practice statement: 2009 update. J Urol (2013) 1.03
Improved biomarkers for prostate cancer: a definite need. J Natl Cancer Inst (2004) 1.02
Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging. J Urol (2009) 1.00
Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging. Urology (2004) 0.98
Association of quantitative magnetic resonance imaging parameters with histological findings from MRI/ultrasound fusion prostate biopsy. Can J Urol (2015) 0.98
Point: Impact of prostate-specific antigen velocity on management decisions and recommendations. J Natl Compr Canc Netw (2013) 0.96
Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages. Urology (2005) 0.95
Expectant treatment with curative intent in the prostate-specific antigen era: triggers for definitive therapy. Urol Oncol (2006) 0.94
Primary care providers' perspectives on discontinuing prostate cancer screening. Cancer (2012) 0.92
Effect of intra-observer variation in prostate volume measurement on prostate-specific antigen density calculations among prostate cancer active surveillance participants. BJU Int (2011) 0.92
Obesity does not adversely affect health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy. Urology (2005) 0.91
Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy. J Urol (2007) 0.90
Update on watchful waiting for prostate cancer. Curr Opin Urol (2004) 0.89
Radical prostatectomy outcome in men 65 years old or older with low risk prostate cancer. J Urol (2012) 0.87
Multiparametric magnetic resonance imaging characterization of prostate lesions in the active surveillance population: incremental value of magnetic resonance imaging for prediction of disease reclassification. J Comput Assist Tomogr (2013) 0.87
Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent. Prostate (2008) 0.86
Association of energy intake with prostate cancer in a long-term aging study: Baltimore Longitudinal Study of Aging (United States). Urology (2003) 0.85
Characteristics and experiences of patients with localized prostate cancer who left an active surveillance program. Patient (2014) 0.83
Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer. BJU Int (2010) 0.83
Informed consent for prostate-specific antigen screening. Urology (2003) 0.83
Significance of prostate adenocarcinoma perineural invasion on biopsy in patients who are otherwise candidates for active surveillance. J Urol (2011) 0.83
Update on PSA testing. J Natl Compr Canc Netw (2007) 0.83
Prostate-specific antigen and all-cause mortality: results from the Baltimore Longitudinal Study On Aging. J Natl Cancer Inst (2004) 0.82
Use of spinal anesthesia does not reduce intraoperative blood loss. Urology (2007) 0.81
Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging. J Urol (2008) 0.80
Prostate volumetric assessment by magnetic resonance imaging and transrectal ultrasound: impact of variation in calculated prostate-specific antigen density on patient eligibility for active surveillance program. J Comput Assist Tomogr (2013) 0.80
Re: an empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 0.80
Repeat prostate biopsies predict location of index cancer in an active surveillance cohort. BJU Int (2011) 0.80
PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. Urology (2002) 0.79
The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate. J Urol (2006) 0.79
The importance of pelvic lymph node dissection in men with clinically localized prostate cancer. Rev Urol (2006) 0.78
Health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy in the phosphodiesterase type 5 ERA: impact of neurovascular bundle preservation. Urology (2005) 0.78
Multiparametric magnetic resonance imaging (MRI) and active surveillance for prostate cancer: future directions. BJU Int (2014) 0.78
Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy. Cancer Res (2007) 0.77
Assessing risk: does this patient have prostate cancer? J Natl Cancer Inst (2006) 0.77
Spinal anesthesia does not impact prostate cancer recurrence in a cohort of men undergoing radical prostatectomy: an observational study. Reg Anesth Pain Med (2014) 0.77
Should prostate-specific antigen velocity be abandoned? Asian J Androl (2011) 0.75
Editorial comment. J Urol (2010) 0.75
Editorial comment. Urology (2009) 0.75
Re: long-term followup after laparoscopic radical nephrectomy. J Urol (2002) 0.75
Editorial comment. J Urol (2012) 0.75
Bone mineral content and prostate cancer risk: data from the Baltimore Longitudinal Study of Aging. BJU Int (2010) 0.75
Helping to address the over treatment of prostate cancer: tools to differentiate lethal and non-lethal phenotype in prostate cancer. Asian J Androl (2012) 0.75
Expectant management of localized prostate cancer. Urology (2003) 0.75
Consultation corner. Prostate screening: refining what PSA levels mean. Johns Hopkins Med Lett Health After 50 (2007) 0.75
Prostate cancer in patients with the bladder exstrophy-epispadias complex: insights and outcomes. Urology (2008) 0.75